Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

Metageno­mi, a genet­ic med­i­cines com­pa­ny with a ver­sa­tile port­fo­lio of whol­ly owned, next-gen­er­a­tion gene edit­ing sys­tems, announced it will present new data dur­ing the 26th Amer­i­can Soci­ety of Gene + Cell Ther­a­py (ASGCT) Annu­al Meet­ing in Los Ange­les (May 16 – 20).

As we advance the field of genet­ic med­i­cines, we need to devel­op nov­el gene edit­ing sys­tems that allow us to address and cor­rect the under­ly­ing dis­ease-caus­ing genes with pre­ci­sion and effi­cien­cy. The data we will present at ASGCT demon­strates the abil­i­ty of our metage­nomics-pow­ered dis­cov­ery plat­form in rapid­ly iden­ti­fy­ing new gene edit­ing tools with unique char­ac­ter­is­tics for ther­a­peu­tic appli­ca­tion,” said Sarah Noon­berg, MD, PhD, Chief Med­ical Offi­cer of Metageno­mi. We look for­ward to show­cas­ing sev­er­al gene edit­ing approach­es, includ­ing updates on our large inte­gra­tion capa­bil­i­ties, nov­el base edit­ing sys­tems, and enhanced edit­ing effi­cien­cies of a lead Type V nucle­ase val­i­dat­ed through non­hu­man pri­mate studies.”

Metageno­mi Pre­sen­ta­tions at ASGCT

A Nov­el Type V CRISPR Sys­tem with Potent Edit­ing Activ­i­ty in Mice and Non-Human Pri­mates (Abstract #229)

  • Oral Pre­sen­ta­tion (Vir­tu­al) – Thurs­day, May 18, 4:00 p.m. – 4:15 p.m. PT
  • Pre­sent­ed by Alan R. Brooks, PhD, Senior Vice Pres­i­dent of Pre­clin­i­cal Research

A Metage­nomics-Derived Gene-Edit­ing Tool­box Enables Effi­cient Genome Engi­neer­ing with Nucle­as­es and Base-Edi­tors in Pri­ma­ry Cells and In Vivo (Abstract #256)

  • Oral Pre­sen­ta­tion – Fri­day, May 19, 3:45 p.m. – 4:00 p.m. PT
  • Pre­sent­ed by Gre­go­ry J. Cost, PhD, Vice Pres­i­dent of Biology

Tar­get­ed Inte­gra­tion to Endoge­nous Sites in the Human Genome Using CRISPR-Asso­ci­at­ed Trans­posas­es Dis­cov­ered from Nat­ur­al Envi­ron­ments (Abstract #1429)

  • Poster Pre­sen­ta­tion – Fri­day, May 19, 12 p.m. PT
  • Pre­sent­ed by Jason Liu, PhD, Sr. Scientist

Full abstracts are avail­able on the ASGCT meet­ing web­site.

About Metageno­mi

Metageno­mi is a gene edit­ing com­pa­ny com­mit­ted to devel­op­ing poten­tial­ly cura­tive ther­a­peu­tics by lever­ag­ing a pro­pri­etary tool­box of next-gen­er­a­tion gene edit­ing sys­tems to accu­rate­ly edit DNA where cur­rent tech­nolo­gies can­not. Our metage­nomics-pow­ered dis­cov­ery plat­form and ana­lyt­i­cal exper­tise reveal nov­el cel­lu­lar machin­ery sourced from oth­er­wise unknown organ­isms. We adapt and forge these nat­u­ral­ly evolved sys­tems into pow­er­ful gene edit­ing sys­tems that are ultra small, extreme­ly effi­cient, high­ly spe­cif­ic and have a decreased risk of immune response. These sys­tems fuel our pipeline of nov­el med­i­cines. Our goal is to rev­o­lu­tion­ize gene edit­ing for the ben­e­fit of patients around the world. For more infor­ma­tion, please vis­it https://​metageno​mi​.co.